The App
NL‐F mouse model of Alzheimer’s Disease demonstrates reduced serum Aß42 levels and Aß42/Aß40 ratio, changes that correlate with CSF Aß levels and cerebral Aß42 plaque load

Recent development of novel assays has made it possible to reliably measure proteins for diagnosis of Alzheimer’s disease (AD) in blood in addition to cerebrospinal fluid (CSF). Previous studies have shown that blood and CSF Aß40 and Aß42 levels correlate in AD patients, and other studies have demonstrated that a reduced plasma Aß42/Aß40 ratio inversely correlates with amyloid burden in the brain (determined by PET). However, more studies are needed to fully understand how these Aß changes in blood correlate with CSF Aß as well as the cerebral Aß plaque load. In this current study, we aim to investigate these associations by the use of a novel knock‐in mouse model, AppNL‐F.